Tangdu Hospital, the Fourth Military Medical University Trials

Tangdu Hospital, the Fourth Military Medical University	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

He, XianLi

KEYNOTE-585 China Extension study, NCT04882241: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Active, not recruiting

120

RoW

Pembrolizumab, MK-3475, KEYTRUDA®, Placebo, Normal saline solution, Cisplatin, PLATINOL®, Capecitabine, XELODA®, 5-fluorouracil, ADRUCIL®, 5FU, Docetaxel, TAXOTERE®, Oxaliplatin, ELOXATIN®, Leucovorin, WELLCOVORIN®

Merck Sharp & Dohme LLC

Gastric Cancer, Gastroesophageal Junction Cancer

02/24

04/25

NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Active, not recruiting

878

RoW

JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy

Shanghai Junshi Bioscience Co., Ltd.

Gastric or Esophagogastric Junction Adenocarcinoma

06/26

07/28

NCT05356520: Comparison of Different Operations for Siewert Type II Adenocarcinoma of Esophagogastric Junction

Recruiting

N/A

212

RoW

Endoscopy Ivor-lewis, Laparoscopic transabdominal enlarged gastrectomy

Xijing Hospital of Digestive Diseases, Tang-Du Hospital, Henan Provincial People's Hospital, General Hospital of Ningxia Medical University, First Affiliated Hospital Xi'an Jiaotong University, The First Affiliated Hospital of Shanxi Medical University

Siewert Type II Adenocarcinoma of Esophagogastric Junction

05/25

05/28

Deng, Jianping

NCT05544045: China Surpass Streamline Post-Market Study

Terminated

N/A

RoW

Surpass Streamline Flow Diverter System

Stryker Neurovascular, Stryker (Beijing) Healthcare Products Co., Ltd

Aneurysm, Intracranial

09/23

Lian, Jianqi

NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

Recruiting

5000

RoW

Peginterferon Alfa-2B, Nucleoside Analogs

Third Affiliated Hospital, Sun Yat-Sen University

Hepatitis B, Chronic

12/26

11/29

ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Active, not recruiting

648

RoW

AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Hepatocellular Carcinoma (HCC)

12/26

NCT05937178: Real-world Study Optimizing Nucleotide-analogues

Recruiting

N/A

20000

RoW

ETV/TAF/TDF/TMF/IFN, ETV/TAF/TDF/TMF

Huashan Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, Beijing YouAn Hospital, Peking University People's Hospital, Peking University First Hospital, Xiamen Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Fujian Medical University, LanZhou University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Hainan General Hospital, Hebei Medical University Third Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Henan Provincial People's Hospital, The Second Affiliated Hospital of Harbin Medical University, Tongji Hospital, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, the Second Hospital of Nangjing, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Hospital of Xuzhou Medical University, The First Affiliated Hospital of Nanchang University, Shengjing Hospital, Qingdao Sixth People's Hospital, Shandong Provincial Hospital Affiliated to Shandong First Medical University, The Second Hospital of Shandong University, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, West China Hospital, Tianjin Second People's Hospital, First Affiliated Hospital of Xinjiang Medical University, The First People's Hospital of Yunnan, Shulan (Hangzhou) Hospital, Zhejiang University, Southwest Hospital, China, The Second Affiliated Hospital of Chongqing Medical University, Sichuan Provincial People's Hospital

Hepatitis B, Chronic

01/29

Zhao, Zhenwei

NCT05898893: PARAT PLUS (The Tubridge Plus For The Treatment Of Wide-Necked Intracranial Aneurysms)

Recruiting

N/A

RoW

Microport NeuroTech Tubridge Plus flow-diverter Stent

MicroPort NeuroTech Co., Ltd.

Intracranial Aneurysm

03/24

12/24

Chang, Ting

NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting

235

Europe, Canada, Japan, US, RoW

Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918

Regeneron Pharmaceuticals

Generalized Myasthenia Gravis

05/25

03/28

SPH-B007-303, NCT06447597: A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.

Recruiting

2/3

104

RoW

B007, Placebo

Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd

Generalized Myasthenia Gravis

06/26

tMG-E, NCT05716035: Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis

Recruiting

2/3

RoW

Tocilizumab Injection

Tang-Du Hospital

Myasthenia Gravis, Generalized

07/24

12/24

tMG, NCT05067348: Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis

Recruiting

RoW

Tocilizumab Injectable Product

Tang-Du Hospital

Myasthenia Gravis, Generalized

03/24

09/24

NCT05343481: Efficacy of VTP-300 in Chronic Hepatitis B Infection

Active, not recruiting

120

RoW

ChAdOx1-HBV, MVA-HBV, Nivolumab, Opdivo 10mg/ml concentrate for solution for infusion

Barinthus Biotherapeutics

Chronic Hepatitis B

02/25

10/26

NCT06371040: Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis

Recruiting

RoW

CD19-BCMA Targeted CAR-T Dose 1, CD19-BCMA Targeted CAR-T Dose 2

Ting Chang, MD

Myasthenia Gravis

03/25

12/26

NCT05581485: Evaluation the Efficiency of Intravenous Dexmedetomidine Under HFNO Without Intubation in Laryngoscope Microsurgery

Recruiting

N/A

RoW

Non-intubated Laryngomicrosurgery

Kaohsiung Veterans General Hospital.

Dexmedetomidine

12/24

NCT06241521: Myasthenia Gravis Registry in China

Recruiting

N/A

1500

RoW

Huashan Hospital, China Alliance for Rare Diseases, National Center for Neurological Disorders (China), China myasthenia gravis collaborating group (CMGCG)

Myasthenia Gravis

02/34

01/35



	Diseases Companies Products Productz Mechanisms of Action Sites